Are International Units of Anti-HBs Antibodies Always Indicative of Hepatitis B Virus Neutralizing Activity?
HBV infectivity neutralization
HBV vaccine
anti-HBs international units
anti-HBs neutralizing activity
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
04 Apr 2023
04 Apr 2023
Historique:
received:
06
03
2023
revised:
31
03
2023
accepted:
01
04
2023
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Anti-HBs antibodies are elicited upon hepatitis B vaccination, and concentrations above 10 mIU/mL are considered protective. Our aim was to assess the relationship between IU/mL of anti-HBs and neutralization activity. Immunoglobulins G (IgGs) were purified from individuals who received a serum-derived vaccine (Group 1), a recombinant vaccine, Genevac-B or Engerix-B (Group 2), or who recovered from acute infection (Group 3). IgGs were tested for anti-HBs, anti-preS1, and anti-preS2 antibodies and for their neutralizing activity in an in vitro infection assay. Anti-HBs IUs/mL value did not strictly correlate with neutralization activity. The Group 1 antibodies demonstrated a greater neutralizing activity than those of Group 2. Anti-preS1 antibodies were detected in Groups 1 and 3, and anti-preS2 in Group 1 and Group 2/Genhevac-B, but the contribution of anti-preS antibodies to neutralization could not be demonstrated. Virions bearing immune escape HBsAg variants were less susceptible to neutralization than wild-type virions. The level of anti-HBs antibodies in IUs is not sufficient to assess neutralizing activity. Consequently, (i) an in vitro neutralization assay should be included in the quality control procedures of antibody preparations intended for HB prophylaxis or immunotherapy, and (ii) a greater emphasis should be placed on ensuring that vaccine genotype/subtype matches with that of the circulating HBV.
Identifiants
pubmed: 37112703
pii: vaccines11040791
doi: 10.3390/vaccines11040791
pmc: PMC10147002
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Maladies infectieuses émergentes
ID : ANRS MIE ECTZ117561
Références
Med Microbiol Immunol. 2015 Feb;204(1):57-68
pubmed: 25557605
J Clin Virol. 2013 Oct;58(2):415-21
pubmed: 23916828
Intervirology. 1978;10(3):196-208
pubmed: 681144
J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S343-S351
pubmed: 34590138
Vaccine. 2018 Jun 7;36(24):3533-3540
pubmed: 29735323
J Virol. 2014 Aug;88(16):9049-59
pubmed: 24899172
Pathol Biol (Paris). 2010 Aug;58(4):288-95
pubmed: 20382485
Vaccine. 2000 Nov 22;19(7-8):943-9
pubmed: 11115720
Arch Virol. 2016 Oct;161(10):2765-72
pubmed: 27439498
Pediatr Infect Dis J. 2014 Sep;33(9):897-903
pubmed: 25361021
Vaccines (Basel). 2021 Apr 01;9(4):
pubmed: 33915943
N Engl J Med. 1997 Jun 26;336(26):1855-9
pubmed: 9197213
Eur J Pediatr. 2014 Sep;173(9):1161-8
pubmed: 24699981
N Engl J Med. 1980 Oct 9;303(15):833-41
pubmed: 6997738
Br Med J (Clin Res Ed). 1986 Jan 18;292(6514):159-61
pubmed: 3080114
J Hepatol. 2016 Apr;64(1 Suppl):S102-S116
pubmed: 27084031
J Virol. 1992 Feb;66(2):1241-5
pubmed: 1309901
Med Microbiol Immunol. 1990;179(1):49-60
pubmed: 1691815
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
J Virol. 2007 Jun;81(11):5841-9
pubmed: 17376925
Methods Mol Biol. 2010;640:463-73
pubmed: 20645068
J Infect. 1986 Jul;13 Suppl A:3-9
pubmed: 2427590
J Exp Med. 2020 Oct 5;217(10):
pubmed: 32579155
J Virol. 2003 Sep;77(17):9511-21
pubmed: 12915565
J Virol. 2018 Jan 30;92(4):
pubmed: 29212929
J Virol. 2009 Sep;83(18):9321-8
pubmed: 19570861
Virol J. 2013 Jul 20;10:239
pubmed: 23870415
Hepatology. 2016 Jan;63(1):35-48
pubmed: 26224662
Hepatology. 2013 Mar;57(3):985-94
pubmed: 23161433